The most exciting part of biotech right now is genomics, and that's reflected in the astronomical stock prices that we've been seeing. But what a lot of people are missing is that there's a lot of work to be done yet. Okay, so we've nearly identified 3 billion base pairs and 100,000 genes. Because, the fact is, those 100,000 genes can translate into 1 million proteins, and those 1 million proteins can be expressed in different environments, in different people, and in different disease states. For whereas genomics is identifying genes and understanding information about genes, proteomics is identifying the proteins those genes make and understanding the functions those proteins perform.
Proteomics is the most critical part.
That gene could translate into 100 different proteins. Its technology isn't perfect, but it's the most cost effective, and it's the most rapid. Going down the road, though, we're going to need something more, something that's more cost effective, and something that's more accurate. So many people within the industry come together, whether its other investors or other colleagues who you can share ideas and information with. Also, you can get up to date on the major companies in the sector, both public and private.